RESORCINOL

Chemical Identification
Chemical Identification
CAS # 108-46-3
Formula

C₆H₆O₂

Synonyms

1,3-benzenediol; m-benzenediol; 1,3-dihydroxybenzene; m-dihydroxybenzene; 3-hydroxyphenol; m-hydroxyphenol

Physical Properties
Physical Properties
Physical description White needles, plates, crystals, flakes, or powder with a faint odor. Turns pink on exposure to light if not completely pure.
Boiling point 531°F Molecular weight 110.11
Freezing point/melting point 228-232°F Vapor pressure 0.0002 mmHg at 77°F
Flash point 261°F Vapor density 3.79
Specific gravity 1.27 at 68°F Ionization potential 8.63 eV
Lower explosive limit (LEL) 1.4% at 738°F Upper explosive limit (UEL) 1.4% at 200°F
NFPA health rating 3 NFPA fire rating 1
NFPA reactivity rating 0 NFPA special instruction
Vapor hazard ratio (VHR)
Historical exceedance percentage
Target organs
Monitoring Methods Used by OSHA
Monitoring Methods Used by OSHA
Analyte code (IMIS no.) 2221
Sampling group
Sampler/Sampling media OSHA versatile sampler (OVS-7) - 13 mm XAD-7 tube (270/140 mg) with GFF enclosed (no longer available) [SKC 226-57]
Sampling time*
Sampling volume (TWA)*

60 L

Sampling flow rate (TWA)*

1 L/min

Sampling volume (STEL/Peak/C)*
Sampling flow rate (STEL/Peak/C)*
Analytical method instruments GC-FID
Method reference OSHA PV2053 (partially validated)
Notes

Media no longer available. SKC recommends the 200/100 mg variant with the same media [SKC 226-57].

Special requirements

* All sampling instructions above are recommended guidelines for OSHA Compliance Safety and Health Officers (CSHOs), please see the corresponding OSHA method reference for complete details.

Wipe Method
Wipe Method
Sampler/Sampling media
Bulk Method
Bulk Method
On-Site Screening Techniques
On-Site Screening Techniques
Device
Model/Type
Sampling information
(see manufacturer instructions)
Exposure Limits
Exposure Limits
OSHA PEL
8-hour TWA
(ST) STEL
(C) Ceiling
Peak
NIOSH REL
Up to 10-hour TWA
(ST) STEL
(C) Ceiling
ACGIH TLV©
8-hour TWA
(ST) STEL
(C) Ceiling
CAL/OSHA PEL
8-hour TWA
(ST) STEL
(C) Ceiling
Peak
PEL-TWA REL-TWA

10 ppm (45 mg/m³)

TLV-TWA

10 ppm [1992]

PEL-TWA

10 ppm (45 mg/m³)

PEL-STEL REL-STEL

20 ppm (90 mg/m³)

TLV-STEL

20 ppm [1992]

PEL-STEL

20 ppm (90 mg/m³)

PEL-C REL-C TLV-C PEL-C
Skin notation

NA

Skin notation

N

Skin notation

N

Skin notation

N

Notes:

Not established

Notes: Notes: Notes:
Health factors:  See NIH-NLM PubChem. IDLH
Carcinogenic classifications: IARC-3, TLV-A4 Notes:
AIHA emergency response planning guidelines - ERPG-1/ERPG-2/ERPG-3:
Additional Resources and Literature References
Additional Resources and Literature References

NOAA: CAMEO Chemicals - Resorcinol

NIOSH: Pocket Guide to Chemical Hazards - Resorcinol

Literature References

  • ACGIH: Documentation of the Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) - Resorcinol. See annual publication for most recent information.
  • Cassano, N., Alessandrini, G., Mastrolonardo, M. and Vena, G.A.: Peeling agents: toxicological and allergological aspects. J. Eur. Acad. Dermatol. Venereol. 13(1): 14-23, 1999.
  • Duran, B., Gursoy, S., Cetin, M., Demirkoprulu, N., Demirel, Y. and Gurelik, B.: The oral toxicity of resorcinol during pregnancy: a case report. J. Toxicol. Clin. Toxicol. 42(5): 663-666, 2004.
  • Hahn, S., Kielhorn, J., Koppenhöfer, J., Wibbertmann, A. and Mangelsdorf, I.: Concise International Chemical Assessment Document 71 Resorcinol.
  • Levin, C.Y. and Maibach, H.: Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am. J. Clin. Dermatol. 2(4): 213-217, 2001.
  • No authors listed: Resorcinol. IARC Monogr. Eval. Carcinog. Risks Hum. 71(Pt. 3): 1119-1131, 1999.
  • No authors: Toxicology and carcinogenesis studies of resorcinol (CAS No. 108-46-3) in F344 rats and B6C3F1 mice (gavage studies). Natl. Toxicol. Program Tech. Rep. Ser. 403: 1-234, 1992.
  • Pohanish, R.P. (editor): Resorcinol. In, Sittig?s Handbook of Toxic and Hazardous Chemicals and Carcinogens, Fourth Ed., Vol. 2. Norwich, NY: Noyes Publications, William Andrew Publishing, 2002, pp. 2000-2002.
  • Yeung, D., Kantor, S., Nacht, S. and Gans, E.H.: Percutaneous absorption, blood levels, and urinary excretion of resorcinol applied topically in humans. Int. J. Dermatol. 22(5): 321-324, 1983.

Last Updated Date : 01/11/2021